Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer | Journal of Clinical Oncology
PURPOSEHormone receptor–positive (HR+) human epidermal growth factor receptor 2–negative (HER2–) endocrine-resistant metastatic breast cancer is treated with sequential single-agent chemotherapy with poor outcomes. Sacituzumab govitecan (SG) is a first-in-…(1) TROPiCS-02 Phase 3 study: #SacituzumabGovitecan improved PFS versus chemotherapy in HR+/HER2– advanced #BreastCancer. (2) At 1 year, 3× as many patients #ProgressionFree with #SacituzumabGovitecan versus chemotherapy.